BusinessCancer Genetics, Inc. is Among the First To Drive New FDA-Approved Testing Paradigm for Non-Small Cell Lung Cancer Patients by Offering Thermo Fisher Scientific’s Oncomine Dx Target TestBy Nasdaq OMXNov 2, 2017, 11:30 AM UTC